Lung Cancer Treatment

Search documents
Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer
Prnewswire· 2025-06-10 11:05
Target Action (PDUFA) Date set for October 7, 2025Application based on data from IMforte, the first Phase 3 trial demonstrating statistically significant and clinically meaningful improvements in both progression-free and overall survival in the ES-SCLC first-line maintenance settingJazz to host investor webcast on Tuesday, June 10 at 4:30 p.m. EDT / 9:30 p.m. IST to review Zepzelca dataFor U.S. media and investors onlyDUBLIN, June 10, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today annou ...
ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study
ZACKS· 2025-05-29 16:55
Shares of ORIC Pharmaceuticals (ORIC) surged more than 20% in the pre-market hours today after announcing potentially best-in-class preliminary efficacy and safety data from the ongoing early-stage study of its novel, once-daily candidate, ORIC-944, for prostate cancer. ORIC-944, in combination with AR inhibitors, J&J’s (JNJ) Erleada (apalutamide) and Bayer’s (BAYRY) Nubeqa (darolutamide), is being evaluated in the phase Ib study for treating patients with metastatic castration-resistant prostate cancer (mC ...
Nuvation Bio (NUVB) - 2025 Q1 - Earnings Call Transcript
2025-05-07 21:32
Nuvation Bio (NUVB) Q1 2025 Earnings Call May 07, 2025 04:30 PM ET Company Participants Robert DeVita - Executive Director, Corporate Development & IRDavid Hung - Founder, President & CEOColleen Sjogren - Chief Commercial OfficerPhilippe Sauvage - CFOMichael Yee - Managing Director Conference Call Participants Gregory Renza - Director & Senior Analyst of Biotechnology Equity ResearchKaveri Pohlman - Managing Director, Senior Equity Research AnalystSoumit Roy - Biotech Research AnalystYaron Werber - Managing ...
Nuvation Bio: A Real Shot To Move The Needle In Lung Cancer Subtypes
Seeking Alpha· 2025-05-07 13:07
Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. I have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech compani ...